Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03411980 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Safety of Vilaprisan in Renal Impairment
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03411980 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 26 participants.
The verdict
NCT03411980, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the pharmacokinetics of vilaprisan in subjects with moderate to severe renal impairment compared with matched subjects with normal renal function.
Interventions
- DRUG Vilaprisan (BAY1002670)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-02-02 |
| Est. Completion | 2019-02-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03411980
The ClinicalTrials.gov registry entry for NCT03411980 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vilaprisan (BAY1002670) is the first listed.
NCT03411980 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03411980 about?
NCT03411980 is a clinical study titled "Pharmacokinetics and Safety of Vilaprisan in Renal Impairment". The purpose of the study is to evaluate the pharmacokinetics of vilaprisan in subjects with moderate to severe renal impairment compared with matched subjects with normal renal function.
What is the current status of trial NCT03411980?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2018-02-02. Estimated completion is 2019-02-06.
What interventions are being tested in trial NCT03411980?
The interventions under investigation include: Vilaprisan (BAY1002670) (DRUG).
Who is sponsoring clinical trial NCT03411980?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.